Found: 28
Select item for more details and to access through your institution.
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1430, doi. 10.1007/s10637-020-00907-4
- By:
- Publication type:
- Article
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1156, doi. 10.1007/s10637-019-00869-2
- By:
- Publication type:
- Article
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 2, p. E49, doi. 10.1002/ajh.24980
- By:
- Publication type:
- Article
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 8, p. E103, doi. 10.1002/ajh.23735
- By:
- Publication type:
- Article
Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 5, p. 487, doi. 10.1002/ajh.23663
- By:
- Publication type:
- Article
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 11, p. 733, doi. 10.1002/ajh.21545
- By:
- Publication type:
- Article
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 9, p. 560, doi. 10.1002/ajh.21482
- By:
- Publication type:
- Article
Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding.
- Published in:
- Oncogene, 2001, v. 20, n. 15, p. 1839, doi. 10.1038/sj.onc.1204259
- By:
- Publication type:
- Article
Bortezomib Inhibits Osteoclast Activity in Patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 9, p. 587
- By:
- Publication type:
- Article
Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation.
- Published in:
- Transplant Infectious Disease, 2017, v. 19, n. 1, p. n/a, doi. 10.1111/tid.12629
- By:
- Publication type:
- Article
MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S346, doi. 10.1016/S2152-2650(21)01805-X
- By:
- Publication type:
- Article
Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01451-8
- By:
- Publication type:
- Article
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S220, doi. 10.1016/j.clml.2019.07.094
- By:
- Publication type:
- Article
A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S208, doi. 10.1016/j.clml.2018.07.063
- By:
- Publication type:
- Article
Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S208, doi. 10.1016/j.clml.2018.07.064
- By:
- Publication type:
- Article
Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S204, doi. 10.1016/j.clml.2018.07.057
- By:
- Publication type:
- Article
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
- Published in:
- Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01553-6
- By:
- Publication type:
- Article
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 12, p. 2814, doi. 10.1002/cam4.1231
- By:
- Publication type:
- Article
Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice.
- Published in:
- PLoS ONE, 2012, v. 7, n. 10, p. 1, doi. 10.1371/journal.pone.0046529
- By:
- Publication type:
- Article
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 6, p. 417, doi. 10.1007/s11899-018-0472-8
- By:
- Publication type:
- Article
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 8, p. 1246, doi. 10.1002/cncr.33338
- By:
- Publication type:
- Article
Dual Receptor T Cells Mediate Pathologic Alloreactivity in Patients with Acute Graft-Versus-Host Disease.
- Published in:
- Science Translational Medicine, 2013, v. 5, n. 188, p. 1, doi. 10.1126/scitranslmed.3005452
- By:
- Publication type:
- Article
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01119-w
- By:
- Publication type:
- Article
Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 1, p. 92, doi. 10.1007/s12185-020-02994-8
- By:
- Publication type:
- Article
Plerixafor.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
- Published in:
- 2018
- By:
- Publication type:
- journal article